AstraZeneca manufacturing employee

44. Enhertu

AstraZeneca and Daiichi Sankyo hoped their antibody-drug conjugate could help a tough-to-treat group of breast cancer patients—and the FDA agreed to give it a shot in late December despite a shaky safety profile.